Shufang Renault

The 12 o’clock assay: an optimized dodecaplex droplet digital PCR assay for robust DNA methylation quantification and epigenetic clock-based age-predictions

Ilef Hchaichi, Imène Garali, Alina-Madalina Popa, Antoine Daunay et autres

Abstract DNA methylation quantification in age-prediction models relies on only a few techniques with inherent limitations and biases, reducing the accuracy and reproducibility. We developed a new droplet digital PCR assay format for accurate DNA methylation quantification, based on three LNA-containing hydrolysis …

fr (code pays fourni par la source)

Additional file 1 of The 12 o’clock assay: an optimized dodecaplex droplet digital PCR assay for robust DNA methylation quantification and epigenetic clock-based age-predictions

Ilef Hchaichi, Imène Garali, Alina-Madalina Popa, Antoine Daunay et autres

Supplementary Material 1.

fr (code pays fourni par la source)

The 12 o’clock assay: an optimized dodecaplex droplet digital PCR assay for robust DNA methylation quantification and epigenetic clock-based age-predictions

Ilef Hchaichi, Imène Garali, Alina-Madalina Popa, Antoine Daunay et autres

Abstract DNA methylation quantification in age-prediction models relies on only a few techniques with inherent limitations and biases, reducing the accuracy and reproducibility. We developed a new droplet digital PCR assay format for accurate DNA methylation quantification, based on three LNA-containing hydrolysis …

fr (code pays fourni par la source)

Additional file 1 of The 12 o’clock assay: an optimized dodecaplex droplet digital PCR assay for robust DNA methylation quantification and epigenetic clock-based age-predictions

Ilef Hchaichi, Imène Garali, Alina-Madalina Popa, Antoine Daunay et autres

Supplementary Material 1.

fr (code pays fourni par la source)

Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafusp

Toulsie Ramtohul, Xavier-Louis Jasawant, José Luis Sandoval, Léah Mailly-Giacchetti et autres

fr (code pays fourni par la source)

Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis

Diana Zhang, Shayesteh Jahanfar, Judy B. Rabinowitz, Joshua Dower et autres

BACKGROUND: Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and carries a worse prognosis relative to other breast cancer subtypes. This systematic review and meta-analysis evaluated the prognostic value of circulating tumor DNA (ctDNA) in early-stage TNBC. METHODS: A …

us, ca, tw, fr (code pays fourni par la source)

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Manuel Jorge Rodrigues, Toulsie Ramtohul, Aurore Rampanou, José Luis Ruiz Sandoval et autres

Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using …

fr (code pays fourni par la source)

Data from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon et autres

AbstractPurpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). …

Supplementary Table Legend 1 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon et autres

Supplementary Table Legend

SupplemetaryFigure1-5 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon et autres

SupplemetaryFigure12345

Supplementary Table 2 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon et autres

Supplementary Table 2

Data from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy

Charles Bobin, Yasmine Iddir, Charlotte Butterworth, Julien Masliah‐Planchon et autres

AbstractPurpose: The study of cell-free DNA (cfDNA) enables sequential analysis of tumor cell–specific genetic alterations in patients with neuroblastoma. Experimental Design: Eighteen patients with relapsing neuroblastoma having received lorlatinib, a third-generation ALK inhibitor, were identified (SACHA national registry and/or in the institution). …